H.I.G. HealthBridge Partners
H.I.G. HealthBridge Partners is a growth equity fund that collaborates with growth-stage healthcare companies to enhance patient outcomes while reducing healthcare costs. The firm focuses on sectors such as medical devices, biopharmaceuticals, digital health, tools and diagnostics, and product-related services. With a seasoned investment team, H.I.G. HealthBridge Partners provides strategic support to its portfolio companies in areas like market strategy, growth initiatives, and operational excellence.
Services
Go-to-market strategy
Assisting portfolio companies in developing and executing effective market entry and expansion strategies.
Inorganic and organic growth initiatives
Supporting portfolio companies in identifying and pursuing growth opportunities, both through internal development and external acquisitions.
Management recruitment
Helping portfolio companies attract and retain top management talent to drive business success.
Operational excellence and expansion
Working with portfolio companies to enhance operational efficiency and support business expansion efforts.
Business development activities
Assisting portfolio companies in identifying and pursuing new business opportunities and partnerships.
Follow-on equity and debt financing
Providing additional financial support to portfolio companies through equity and debt financing options.
Go-to-market strategy
Assisting portfolio companies in developing and executing effective market entry and expansion strategies.
Inorganic and organic growth initiatives
Supporting portfolio companies in identifying and pursuing growth opportunities, both through internal development and external acquisitions.
Management recruitment
Helping portfolio companies attract and retain top management talent to drive business success.
Operational excellence and expansion
Working with portfolio companies to enhance operational efficiency and support business expansion efforts.
Business development activities
Assisting portfolio companies in identifying and pursuing new business opportunities and partnerships.
Follow-on equity and debt financing
Providing additional financial support to portfolio companies through equity and debt financing options.
Portfolio
Awarded 'Most Innovative Product of the Year' by Best in Biz for CYTALUX® (pafolacianine) injection.
#Healthcare
H.I.G. Capital completed the sale of BIOVECTRA, a leading company in its sector.
#Healthcare
Received start-up financing of $207.8 million, one of the largest initial financing commitments for a European-focused biopharmaceutical company.
#Biopharmaceuticals
Developed the OverStitch™ Endoscopic Suturing System, a new class of flexible surgical instruments.
#Medical Devices
Pioneer in augmented reality surgical navigation, raised $82.5 million to accelerate adoption of augmented reality spine surgery.
#Medical Devices
Awarded 'Most Innovative Product of the Year' by Best in Biz for CYTALUX® (pafolacianine) injection.
#Healthcare
H.I.G. Capital completed the sale of BIOVECTRA, a leading company in its sector.
#Healthcare
Received start-up financing of $207.8 million, one of the largest initial financing commitments for a European-focused biopharmaceutical company.
#Biopharmaceuticals
Developed the OverStitch™ Endoscopic Suturing System, a new class of flexible surgical instruments.
#Medical Devices
Pioneer in augmented reality surgical navigation, raised $82.5 million to accelerate adoption of augmented reality spine surgery.
#Medical Devices